Medical and Pharmaceutical Eli Lilly inks USD$2.75B AI drug deal with Insilico Medicine Insilico has developed at least 28 drug candidates using generative AI tools Joseph Morton10 hours ago
Medical and Pharmaceutical Eli Lilly funds Indigenous lung health education initiative in North America 'Healthy Workforce, Productive Community' will extend for 3 years Rowan DunneMarch 25, 2026
Medical and Pharmaceutical bioAffinity Technologies soars Monday as non-invasive lung cancer tech gains traction Shares rose by 73% during the session with no immediate catalyst Rowan DunneMarch 23, 2026
Medical and Pharmaceutical Bacterial infection breath test demonstrates efficacy in rodent studies It can provide results within 10 minutes Rowan DunneMarch 18, 2026
Medical and Pharmaceutical Guardant Health launches multi-cancer blood test in Asia through Manulife partnership Cancer remains a leading cause of death across Asia, driving demand for early screening tools Joseph MortonMarch 18, 2026
Medical and Pharmaceutical Immutep completely tanks after discontinuing lung cancer drug trial Shares dropped by 88% on Friday the 13th, leaving investors shook Rowan DunneMarch 16, 2026
Medical and Pharmaceutical FDA clears Median Technologies lung-nodule risk assessment software The Median system reported 93.3 per cent sensitivity and 92.4 per cent specificity when identifying malignant lung nodules Joseph MortonMarch 16, 2026
Medical and Pharmaceutical bioAffinity launches 2,000-patient study for noninvasive lung cancer test The test analyzes sputum samples using flow cytometry to identify cancer-related cellular changes Joseph MortonMarch 11, 2026
Medical and Pharmaceutical Tango Therapeutics rallies after oncology drug collaboration with Erasca Researchers think combining both drugs could create stronger and longer-lasting tumor responses Joseph MortonMarch 5, 2026
Medical and Pharmaceutical Optellum breaks new ground with TGA approval for AI-powered lung nodule solution 'Radiological computer-assisted diagnostic software for lesions suspicious of cancer' is what the FDA calls it Rowan DunneMarch 5, 2026